Lilly says weight loss drug cuts heart failure risk by 38% in trial ReutersLilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and CompanyEli Lilly Finds Yet Another Condition for Zepbound to Treat. The Stock Is Up. Barron’sEli Lilly says tirzepatide showed positive results in late-stage trial evaluating it as treatment for heart failure MarketWatch